[
  {
    "statement": "Antibiotic.",
    "reference_no": "None",
    "reference": "No citation identified in the source text.",
    "matched_paper": "None",
    "matched_evidence": "The system could not identify a superscript or citation number for this specific statement in the PDF.",
    "validation_result": "Refuted",
    "page_location": "N/A",
    "confidence_score": 0.0,
    "matching_method": "",
    "analysis_summary": "This statement was extracted but has no linked reference number to validate against.",
    "confidence_band": "LOW"
  },
  {
    "statement": "amikacin. 3.5-5.5. Local site pain. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,2,3",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 2.Amikacin Side Effects_ Common, Severe, Long Term.pdf: Common (1% to 10%): Injection site pain[Ref]\n- 3.Amikin (Amikacin)_ Side Effects, Uses, Dosage, Interactions, Warnings.pdf: The 100 mg per 2 mL vial, each mL contains: 50 mg Amikacin(as the sulfate), 0.13% Sodium Metabisulfite, 0.5% Sodium Citrate Dihydrate, Water for Injections, Air replaced with Nitrogen. pH is adjusted with Sulfuric Acid and/or if necessary Sodium Hydroxide. pH 3.5-5.5.|The 500 mg per 2 mL vial and the 1 gram per 4 mL vial, each mL contains: 250 mg Amikacin(as the sulfate), 0.66% Sodium Metabisulfite, 2.5% Sodium Citrate Dihydrate, Water for Injection qs, Air replaced with Nitrogen. pH is adjusted with Sulfuric Acid and/or if necessary Sodium Hydroxide. pH 3.5-5.5.|injection site reactions (pain, irritation, redness).|Amikacin should not be physically premixed with other drugs but should be administered separately according to the recommended dosage and route.",
    "validation_result": "Supported",
    "page_location": "Page 6, under the heading \"Local\" | Page 3, Page 1, Page 5",
    "confidence_score": 0.925,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "ampicillin. 8.0-10.0. Phlebitis. Local site pain. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "4,5,6,7",
    "reference": "",
    "matched_paper": "Multiple PDFs (4/4 support)",
    "matched_evidence": "- 7.Omnipen-N injection Uses, Side Effects & Warnings.pdf: Omnipen-N is injected into a muscle, or into a vein through an IV.\n- 4.Ampicillin injections SPC.pdf: Ampicillin solutions should always be administered separately, unless compatibility\nwith other infusion solutions or medicines has been established.\n- 5.Ampicillin - StatPearls - NCBI Bookshelf.pdf: Local Adverse Reactions | • Pain at IM/IV injection site | • Thrombophlebitis\n- 6.Ampicillin_ Package Insert _ Prescribing Information.pdf: The pH range of the reconstituted solution is 8 to 10.",
    "validation_result": "Supported",
    "page_location": "Page 2, How is Omnipen-N given? | Page 5, Section 6.2 Incompatibilities | Page 5, under Adverse Effects, Local Adverse Reactions | Page 2, under Ampicillin - Clinical Pharmacology",
    "confidence_score": 0.7999999999999999,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 4 sources",
    "confidence_band": "MEDIUM"
  },
  {
    "statement": "ampicillin and sulbactam. 8.0-10.0. Phlebitis. Local site pain. Rotation of peripheral infusion sites recommended. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "8,9",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 8.Ampicillin and Sulbactam Injection_ Package Insert _ Prescribing Info.pdf: The pH of the solutions is between 8 and 10.|Phlebitis - 1.2%|Pain at IV injection site - 3%\n- 9.Ampicillin and Sulbactam Injection_ Package Insert _ Prescribing Info.pdf: The pH of the solutions is between 8 and 10.|Phlebitis - 1.2%|Pain at IV injection site - 3%",
    "validation_result": "Supported",
    "page_location": "Page 2, Page 10, Page 10 | Page 2, Page 10, Page 10",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "azithromycin. NR*. Potential for damage from extravasation. Local site pain. Redness at injection site. Rotation of peripheral infusion sites recommended. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,9",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 9.Ampicillin and Sulbactam Injection_ Package Insert _ Prescribing Info.pdf: Pain at IV injection site - 3%",
    "validation_result": "Supported",
    "page_location": "Page 10, under \"Adverse Reactions/Side Effects\", \"Adult Patients\", \"Local Adverse Reactions\"",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "aztreonam. 4.5-7.5. Phlebitis. Thrombo-phlebitis. Local site pain. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,10",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 10.Aztreonam_ Package Insert _ Prescribing Information.pdf: Aqueous solutions of the product have a pH in the range of 4.5 to 7.5.|Local reactions such as phlebitis/thrombophlebitis following intravenous administration, and discomfort/swelling at the injection site following intramuscular administration occurred at rates of approximately 1.9% and 2.4%, respectively.|In 343 pediatric patients receiving intravenous therapy, the following local reactions were noted: pain (12%), erythema (2.9%), induration (0.9%), and phlebitis (2.1%).|With any intermittent infusion of aztreonam and another drug with which it is not pharmaceutically compatible, the common delivery tube should be flushed before and after delivery of aztreonam with any appropriate infusion solution compatible with both drug solutions; the drugs should not be delivered simultaneously.",
    "validation_result": "Supported",
    "page_location": "Page 2, 12, 13, 17",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "aztreonam and avibactam sodium. 4.0-8.0. Phlebitis. Thrombo-phlebitis. Potential for damage from extravasation. Local site pain. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "11",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 11.Collins SR, Azithromycin.pdf: Monitor infusion Page 136 site for inflammation and/or extravasation.",
    "validation_result": "Supported",
    "page_location": "Page 5, Monitor section",
    "confidence_score": 0.75,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "MEDIUM"
  },
  {
    "statement": "capreomycin. 4.5-7.0. Phlebitis. Thrombo-phlebitis. Local site pain. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "12,13",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 12.Capreomycin.pdf: Signs of potential side effects, especially nephrotoxicity; hypersensitivity; hypokalemia; neuromuscular blockade; auditory and vestibular ototoxicity; and pain, hardness, unusual bleeding, or a sore at the place of injection [FDA label].\n- 13.Capreomycin_ Package Insert _ Prescribing Information.pdf: Pain and induration at the injection site have been observed.",
    "validation_result": "Supported",
    "page_location": "Page 2, Human potential toxicity and Human adverse reactions | Page 6, Adverse Reactions/Side Effects",
    "confidence_score": 0.8,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "cefazolin. 4.0-6.0. Phlebitis. Thrombo-phlebitis. Local site pain. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,14",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 14.Cefazolin Injection_ Package Insert _ Prescribing Info.pdf: Rare instances of phlebitis have been reported at site of injection. |Pain at the site of injection after intramuscular administration has occurred infrequently.",
    "validation_result": "Supported",
    "page_location": "Page 8, under Adverse Reactions/Side Effects",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "cefepime. 5.2-5.8. Phlebitis. Thrombo-phlebitis. Local site pain. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,15",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 15.Cefepime_ Package Insert _ Prescribing Information.pdf: Local adverse reactions (3%), including phlebitis (1.3%), pain and/or inflammation (0.6%)*; rash (1.1%)",
    "validation_result": "Supported",
    "page_location": "Page 13, Table 5: Adverse Reactions in Cefepime Multiple-Dose Dosing Regimens Clinical Trials in North America",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "cefiderocol sulfate tosylate. 5.0-7.5. Phlebitis. Thrombo-phlebitis. Potential for damage from extravasation. Local site pain. Redness at injection site. Rotation of peripheral infusion sites recommended. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,16,17",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 16.Fetroja (Cefiderocol for Injection)_ Side Effects, Uses, Dosage, Interactions, Warnings.pdf: The pH of the reconstituted solution of 1gram cefiderocol (1 vial) dissolved in 10 mL water is 5.2 to 5.8.|Infusion site reactions include infusion site erythema, inflammation, pain, pruritis, injection site pain, and phlebitis.\n- 17.Fetroja_ Package Insert _ Prescribing Information.pdf: Infusion site reactions include infusion site erythema, inflammation, pain, pruritis, injection site pain, and phlebitis.",
    "validation_result": "Supported",
    "page_location": "Page 4, Page 8 | Page 10, Table 4",
    "confidence_score": 0.925,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "cefotaxime sodium. 4.5-6.5. Phlebitis. Thrombo-phlebitis. Local site pain. Rotation of peripheral infusion sites recommended. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,18,19",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 18.Cefotaxime_ Package Insert _ Prescribing Information.pdf: Solutions of Cefotaxime for Injection, USP range from very pale yellow to light amber depending on the concentration and the diluent used. The pH of the injectable solutions usually ranges from 5.0 to 7.5.|General disorders and administration site conditions - Inflammatory reactions at the injection site, including phlebitis/thrombophlebitis.|Cefotaxime, like other parenteral anti-infective drugs, may be locally irritating to tissues. In most cases, perivascular extravasation of cefotaxime responds to changing of the infusion site. In rare instances, extensive perivascular extravasation of cefotaxime may result in tissue damage and require surgical treatment. To minimize the potential for tissue inflammation, infusion sites should be monitored regularly and changed when appropriate.|NOTE: Solutions of cefotaxime must not be admixed with aminoglycoside solutions. If cefotaxime and aminoglycosides are to be administered to the same patient, they must be administered separately and not as mixed injection.\n- 19.Cefotaxime_ Package Insert _ Prescribing Information.pdf: Solutions of Cefotaxime for Injection, USP range from very pale yellow to light amber depending on the concentration and the diluent used. The pH of the injectable solutions usually ranges from 5.0 to 7.5.|General disorders and administration site conditions - Inflammatory reactions at the injection site, including phlebitis/thrombophlebitis.|Cefotaxime, like other parenteral anti-infective drugs, may be locally irritating to tissues. In most cases, perivascular extravasation of cefotaxime responds to changing of the infusion site. In rare instances, extensive perivascular extravasation of cefotaxime may result in tissue damage and require surgical treatment. To minimize the potential for tissue inflammation, infusion sites should be monitored regularly and changed when appropriate.|NOTE: Solutions of cefotaxime must not be admixed with aminoglycoside solutions. If cefotaxime and aminoglycosides are to be administered to the same patient, they must be administered separately and not as mixed injection.",
    "validation_result": "Supported",
    "page_location": "Page 1, Page 11, Page 8, Page 14 | Page 1, Page 11, Page 8, Page 14",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "cefotetan disodium. 4.2-7.0. Phlebitis. Thrombo-phlebitis. Local site pain. Rotation of peripheral infusion sites recommended. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,20",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 20.Cefotan_ Package Insert _ Prescribing Information.pdf: The pH of freshly reconstituted solutions is usually between 4.5 to 6.5.|Local: effects were reported in less than 1% of patients and included phlebitis at the site of injection (1 in 300), and discomfort (1 in 500).|NOTE: Solutions of cefotetan must not be admixed with solutions containing aminoglycosides. If CEFOTAN® and aminoglycosides are to be administered to the same patient, they must be administered separately and not as a mixed injection.",
    "validation_result": "Supported",
    "page_location": "Page 2, Page 12, Page 16",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "cefoxitin. 4.5-6.5. Phlebitis. Thrombo-phlebitis. Local site pain.",
    "reference_no": "1,21",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 21.Cefoxitin Package Insert Prescribing Information.pdf: The pH of freshly constituted solutions usually ranges from 4.2 to 7.0.|Thrombophlebitis has occurred with intravenous administration.",
    "validation_result": "Supported",
    "page_location": "Page 2, Page 9",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "cefoperazone. 4.8-6.5. Phlebitis. Thrombo-phlebitis. Local site pain.",
    "reference_no": "1,22,23",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 22.Cefobide.pdf: The pH of a 25% (w/v) freshly reconstituted solution varies between 4.5–6.5|When CEFOBID is administered by intravenous infusion some patients may develop phlebitis (1 in 120) at the infusion site.|Occasionally, transient pain (1 in 140) may follow administration by this route.\n- 23.Cefoperazone Side Effects_ Common, Severe, Long Term.pdf: Local side effects have included pain after intramuscular injection and phlebitis after intravenous infusion.",
    "validation_result": "Supported",
    "page_location": "Page 1, Page 12 | Page 2, under the 'Local' section",
    "confidence_score": 0.925,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "ceftaroline fosamil. 5.0-8.0. Phlebitis. Local site pain. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,24",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 24.Teflaro Package Insert  Prescribing Information.pdf: Table 6 lists adverse reactions occurring in ≥ 2% of patients receiving Teflaro in the pooled adult Phase 3 clinical trials.|Phlebitis 2% 1%",
    "validation_result": "Supported",
    "page_location": "Page 10, Table 6",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "ceftazidime.",
    "reference_no": "1,25",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 25.Ceftazidime Package Insert  Prescribing Information.pdf: Ceftazidime: Package Insert / Prescribing Info|To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftazidime for injection and other antibacterial drugs, ceftazidime for injection should be used only to treat infections that are proven or strongly suspected to be caused by bacteria.|Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibacterial drug for parenteral administration.",
    "validation_result": "Supported",
    "page_location": "Page 1",
    "confidence_score": 1.0,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "amikacin. Additional Consideration. Do not physically premix with other drugs; administer separately as recommended by manufacturer. Inactivated in solution with beta-lactam antibiotics (e.g., cephalosporins, penicillins) and vancomycin. Do not mix in the same solution. Appropriate spacing required because of physical incompatibilities.¹",
    "reference_no": "1,2,3",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/2 support)",
    "matched_evidence": "- 3.Amikin (Amikacin)_ Side Effects, Uses, Dosage, Interactions, Warnings.pdf: Amikacin should not be physically premixed with other drugs but should be administered separately according to the recommended dosage and route.|In vitro mixing of aminoglycosides with beta-lactam antibiotics (penicillin or cephalosporin) may result in a significant mutual inactivation.",
    "validation_result": "Supported",
    "page_location": "Page 5, Page 8",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "ampicillin 4,5,6,7. Additional Consideration. Ampicillin solutions should always be administered separately, unless compatibility with other infusion solutions or medicines has been established. Ampicillin solutions should not be mixed with aminoglycosides, metronidazole and injectable tetracycline derivatives such as oxytetracycline, rolitetracycline and doxycycline. Visual signs of incompatibility are precipitation, clouding and discoloration.6",
    "reference_no": "4,5,6,7",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/4 support)",
    "matched_evidence": "- 4.Ampicillin injections SPC.pdf: Ampicillin solutions should always be administered separately, unless compatibility with other infusion solutions or medicines has been established.|Ampicillin solutions should not be mixed with aminoglycosides, metronidazole and injectable tetracycline derivatives such as oxytetracycline, rolitetracycline and doxycycline.|Visual signs of incompatibility are precipitation, clouding and discoloration.",
    "validation_result": "Supported",
    "page_location": "Page 5, Section 6.2 Incompatibilities",
    "confidence_score": 1.0,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 4 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "ampicillin and sulbactam 8,9. Additional Consideration. Frequently used concomitantly with aminoglycosides (e.g., gentamicin), but these drugs must never be mixed in the same infusion (mutual inactivation). If given concurrently, administer at separate sites.¹",
    "reference_no": "8,9",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 8.Ampicillin and Sulbactam Injection_ Package Insert _ Prescribing Info.pdf: Ampicillin and sulbactam for injection and aminoglycosides should be reconstituted and administered separately, due to the in vitro inactivation of aminoglycosides by any of the aminopenicillins.\n- 9.Ampicillin and Sulbactam Injection_ Package Insert _ Prescribing Info.pdf: Ampicillin and sulbactam for injection and aminoglycosides should be reconstituted and administered separately, due to the in vitro inactivation of aminoglycosides by any of the aminopenicillins.",
    "validation_result": "Supported",
    "page_location": "Page 14, Compatibility, Reconstitution and Stability | Page 14, section: COMPATIBILITY, RECONSTITUTION AND STABILITY",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "azithromycin 1,9. Additional Consideration. Manufacturer states, \"Other IV substances, additives, or medications should not be added to azithromycin, or infused simultaneously through the same IV line.\" Flush IV line with a compatible IV fluid before and after administration. ¹ Local IV site reactions have been reported with the intravenous administration of azithromycin. All volunteers who received infusate concentrations above 2.0 mg/mL experienced local IV site reactions and, therefore, higher concentrations should be avoided. 9",
    "reference_no": "1,9",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 9.Ampicillin and Sulbactam Injection_ Package Insert _ Prescribing Info.pdf: Pain at IV injection site - 3%",
    "validation_result": "Supported",
    "page_location": "Page 10, under Adverse Reactions/Side Effects, Local Adverse Reactions",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "aztreonam 1,10. Additional Consideration. Do not infuse simultaneously with other drugs or solutions except in proven compatibility.¹",
    "reference_no": "1,10",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 10.Aztreonam_ Package Insert _ Prescribing Information.pdf: With any intermittent infusion of aztreonam and another drug with which it is not pharmaceutically compatible, the common delivery tube should be flushed before and after delivery of aztreonam with any appropriate infusion solution compatible with both drug solutions; the drugs should not be delivered simultaneously.",
    "validation_result": "Supported",
    "page_location": "Page 17, Intravenous Administration, Infusion",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "aztreonam and avibactam sodium11. Additional Consideration. Emblaveo is administered by intravenous infusion over 3 hours. This medicinal product must not be mixed with other medicinal products except sodium chloride (0.9%) solution for injection, glucose (5%) solution for injection, or Lactated Ringer's solution as mentioned below.11",
    "reference_no": "11",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 11.Collins SR, Azithromycin.pdf: No relevant information about aztreonam and avibactam sodium, administration time, or compatible solutions is found in the provided document.",
    "validation_result": "Not Found",
    "page_location": "N/A",
    "confidence_score": 0.0,
    "matching_method": "Aggregated (Not Found)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "LOW"
  },
  {
    "statement": "capreomycin 12,13. Additional Consideration. May be used concomitantly with aminoglycosides (e.g., amikacin, gentamicin), but these drugs must never be mixed in the same infusion (mutual inactivation). If given concurrently, administer separately and flush IV line before and after administration.¹",
    "reference_no": "12,13",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/2 support)",
    "matched_evidence": "- 12.Capreomycin.pdf: There is an increased risk of damage to the kidneys and ears if capreomycin is taken with vancomycin, cisplatin, or aminoglycoside antibiotics.",
    "validation_result": "Supported",
    "page_location": "Page 2, under Human drug-drug interactions",
    "confidence_score": 0.75,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "MEDIUM"
  },
  {
    "statement": "cefazolin 1,14. Additional Consideration. Temporarily discontinuing other solutions infusing at the same site during intermittent infusion. May be used concomitantly with aminoglycosides (e.g., gentamicin, tobramycin), aminophylline, metronidazole, and vancomycin, but these drugs must never be mixed in the same infusion (mutual inactivation or other potential interactions). If concurrent therapy with cefepime is indicated, each of these antibiotics can be administered separately.¹",
    "reference_no": "1,14",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 14.Cefazolin Injection_ Package Insert _ Prescribing Info.pdf: None",
    "validation_result": "Not Found",
    "page_location": "",
    "confidence_score": 0.1,
    "matching_method": "Aggregated (Not Found)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "LOW"
  },
  {
    "statement": "cefepime 1,15. Additional Consideration. May be used concomitantly with aminoglycosides (e.g., amikacin, gentamicin), but these drugs must never be mixed in the same infusion (mutual inactivation). If given concurrently, administer separately and flush the IV line before and after administration.¹",
    "reference_no": "1,15",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 15.Cefepime_ Package Insert _ Prescribing Information.pdf: Do not add solutions of cefepime for injection, to solutions of ampicillin at a concentration greater than 40 mg per mL, or to metronidazole, vancomycin, gentamicin, tobramycin, netilmicin sulfate, or aminophylline because of potential interaction. However, if concurrent therapy with cefepime for injection is indicated, each of these antibiotics can be administered separately.",
    "validation_result": "Supported",
    "page_location": "Page 10, Drug Interactions",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "cefiderocol sulfate tosylate 1,16,17. Additional Consideration. Solutions of cefotetan must not be admixed with solutions containing aminoglycosides. If Cefotan and aminoglycosides are to administered to the same patient, they must be administered separately and not as a mixed injection.20",
    "reference_no": "1,16,17",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 16.Fetroja (Cefiderocol for Injection)_ Side Effects, Uses, Dosage, Interactions, Warnings.pdf: None\n- 17.Fetroja_ Package Insert _ Prescribing Information.pdf: None",
    "validation_result": "Not Found",
    "page_location": "",
    "confidence_score": 0.05,
    "matching_method": "Aggregated (Not Found)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "LOW"
  },
  {
    "statement": "cefotaxime sodium 1,18,19. Additional Consideration. May be used concomitantly with aminoglycosides (e.g., amikacin, gentamicin), but these drugs must never be mixed in the same infusion (mutual inactivation). If given concurrently, administer separately and flush the IV line before and after administration.¹",
    "reference_no": "1,18,19",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 18.Cefotaxime_ Package Insert _ Prescribing Information.pdf: NOTE: Solutions of cefotaxime must not be admixed with aminoglycoside solutions. If cefotaxime and aminoglycosides are to be administered to the same patient, they must be administered separately and not as mixed injection.\n- 19.Cefotaxime_ Package Insert _ Prescribing Information.pdf: NOTE: Solutions of cefotaxime must not be admixed with aminoglycoside solutions. If cefotaxime and aminoglycosides are to be administered to the same patient, they must be administered separately and not as mixed injection.",
    "validation_result": "Supported",
    "page_location": "Page 14, Preparation of cefotaxime for injection sterile | Page 14, Preparation of cefotaxime for injection sterile",
    "confidence_score": 1.0,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "cefotetan disodium 1,20. Additional Consideration. May be used concomitantly with aminoglycosides (e.g., amikacin, gentamicin), but these drugs must never be mixed in the same infusion (mutual inactivation). If given concurrently, administer separately and flush the IV line before and after administration.¹",
    "reference_no": "1,20",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 20.Cefotan_ Package Insert _ Prescribing Information.pdf: NOTE: Solutions of cefotetan must not be admixed with solutions containing aminoglycosides. |If CEFOTAN® and aminoglycosides are to be administered to the same patient, they must be administered separately and not as a mixed injection.",
    "validation_result": "Supported",
    "page_location": "Page 16, Intravenous Administration section",
    "confidence_score": 1.0,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "cefoxitin 1,21. Additional Consideration. Solutions of CEFOBID and aminoglycoside should not be directly mixed, since there is a physical incompatibility between them. 22",
    "reference_no": "1,21",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 21.Cefoxitin Package Insert Prescribing Information.pdf: Solutions of Cefoxitin for Injection, USP range from colorless to light amber in color.|The pH of freshly constituted solutions usually ranges from 4.2 to 7.0.|Solutions of Cefoxitin for Injection, like those of most beta-lactam antibiotics, should not be added to aminoglycoside solutions (e.g., gentamicin sulfate, tobramycin sulfate, amikacin sulfate) because of potential interaction.",
    "validation_result": "Supported",
    "page_location": "Page 2, Page 14",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "cefoperazone 1,22,23. Additional Consideration. Manufacturer states, Should not be mixed with or physically added to solutions containing other drugs.¹",
    "reference_no": "1,22,23",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/2 support)",
    "matched_evidence": "- 22.Cefobide.pdf: Solutions of CEFOBID and aminoglycoside should not be directly mixed, since there is a physical incompatibility between them.",
    "validation_result": "Supported",
    "page_location": "Page 13, Dosage and Administration section",
    "confidence_score": 1.0,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "ceftaroline fosamil 1,24. Additional Consideration. May be used concomitantly with aminoglycosides (e.g., amikacin, gentamicin, and tobramycin), but these drugs must never be mixed in the same infusion (mutual inactivation). May exhibit a physical incompatibility with vancomycin depending on concentration. If aminoglycosides or vancomycin are given concurrently, administer separately and flush IV line before and after administration. Manufacturer recommends temporarily discontinuing other solutions infusing at the same site during intermittent infusion and states, \"Do not add supplementary medications to premixed plastic IV containers.¹",
    "reference_no": "1,24",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 24.Teflaro Package Insert  Prescribing Information.pdf: The compatibility of Teflaro with other drugs has not been established. Teflaro should not be mixed with or physically added to solutions containing other drugs.",
    "validation_result": "Supported",
    "page_location": "Page 7, section 2.6 Drug Compatibilities",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "ceftazidime 1,25. Additional Consideration. May be used concomitantly with aminoglycosides (e.g., amikacin, gentamicin), but these drugs must never be mixed in the same infusion (mutual inactivation). If given concurrently, administer separately and flush the IV line before and after administration.¹",
    "reference_no": "1,25",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 25.Ceftazidime Package Insert  Prescribing Information.pdf: Solutions of ceftazidime for injection, like those of most beta-lactam antibacterial drugs, should not be added to solutions of aminoglycoside antibacterial drugs because of potential interaction.|However, if concurrent therapy with ceftazidime for injection and an aminoglycoside is indicated, each of these antibacterial drugs can be administered separately to the same patient.",
    "validation_result": "Supported",
    "page_location": "Page 14, Compatibility and Stability section",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "ceftizoxime. Phlebitis. Local site pain on Infusion. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "26,27",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 26.Ceftizoxime Uses, Side Effects & Warnings.pdf: • severe pain, burning, irritation, or skin changes where the needle was placed;|• pain, irritation, or hardening where the injection was given;\n- 27.Ceftizoxime Side Effects_ Common, Severe, Long Term.pdf: Local side effects have included burning, cellulitis, phlebitis, pain, induration, tenderness, and paresthesia at the injection site in 1% to 5% of patients.",
    "validation_result": "Supported",
    "page_location": "Page 3 and 4 | Page 3, under the 'Local' section",
    "confidence_score": 0.925,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "ceftobiprole medocaril\nsodium. 4.5-5.5. Thrombosis of vessel. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,28,29",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 28.Ceftobiprole Medocaril Side Effects_ Common, Severe, Long Term.pdf: Applies to ceftobiprole medocaril: intravenous powder for injection.|• Frequency not reported: Thrombosis\n- 29.ZEVTERA (ceftobiprole medocaril) Highlights of Prescribing Information. U.S. Food and Drug Administration..pdf: The pH of the reconstituted solution is 4.5–5.5.",
    "validation_result": "Supported",
    "page_location": "Page 1, Page 2 | Page 21, Description section",
    "confidence_score": 0.85,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "ceftolozane/tazobactam. 5.0-7.0. Phlebitis. Thrombosis of vessel. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,30",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 30.Zerbaxa.pdf: Tazobactam sodium is a white to off-white, hygroscopic powder, that is freely soluble in water and slightly soluble in ethanol and acetone. The pH of an aqueous solution of the drug substance is 5.0-7.0.|ZERBAXA (ceftolozane/tazobactam) should not be infused simultaneously with other medications via the same intravenous line.|Phlebitis5 4 (6) 0 (0) 1 (1) 1 (3) *In the clAl trials, ZERBAXA (ceftolozane/tazobactam) was given in conjunction with metronidazole. 5 Includes superficial phlebitis.|Vascular disorders: venous thrombosis",
    "validation_result": "Supported",
    "page_location": "Page 1, Page 2, Page 13, Page 11",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "ceftriaxone. 6.6-6.7. Phlebitis. Local site pain on Infusion. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,31",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 31..Ceftriaxone Package Insert  Prescribing Information.pdf: The pH of a 1% aqueous solution is approximately 6.7.|Pain, induration and tenderness was 1% overall. Phlebitis was reported in <1% after IV administration.|Injection site pain (0.6%)",
    "validation_result": "Supported",
    "page_location": "Page 1, Page 13",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "cefuroxime. 5.0-8.5. Thrombo-phlebitis. Local site pain on Infusion. Rotation of peripheral infusion sites recommended. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,32",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 32.Cefuroxime Injection Package Insert  Prescribing Info.pdf: The pH of freshly constituted solutions usually ranges from 6 to 8.5.|Thrombophlebitis has occurred with IV administration in 1 in 60 patients.|For intermittent IV infusion with a Y-type administration set, dosing can be accomplished through the tubing system by which the patient may be receiving other IV solutions. |However, during infusion of the solution containing Cefuroxime for Injection, it is advisable to temporarily discontinue administration of any other solutions at the same site.",
    "validation_result": "Supported",
    "page_location": "Page 2, Page 8, Page 12",
    "confidence_score": 0.85,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "chloramphenicol\nsodium succinate. 6.4-7.0. Local site pain on Infusion. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,33",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 33.Chloramphenicol_ Indications, Side Effects, Warnings - Drugs.com.pdf: [No evidence text provided]",
    "validation_result": "Not Found",
    "page_location": "Throughout the document",
    "confidence_score": 0.2,
    "matching_method": "Aggregated (Not Found)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "LOW"
  },
  {
    "statement": "ciprofloxacin. 3.5-4.6. Thrombo-phlebitis. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,34",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 34.Ciprofloxacin Injection Package Insert  Prescribing.pdf: The pH range for the 0.2% ready-for-use infusion solutions is 3.5 to 4.6.|The following adverse reactions have been reported from worldwide marketing experience with fluoroquinolones, including ciprofloxacin.|Thrombophlebitis|Ciprofloxacin injection should be administered by intravenous infusion over a period of 60 minutes.|Slow infusion of a dilute solution into a larger vein will minimize patient discomfort and reduce the risk of venous irritation.",
    "validation_result": "Supported",
    "page_location": "Page 32, Page 21, Page 12",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "clarithromycin. Phlebitis. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "35",
    "reference": "",
    "matched_paper": "None",
    "matched_evidence": "No matching reference PDF was found for the extraction: 35",
    "validation_result": "Reference Missing",
    "page_location": "N/A",
    "confidence_score": 0.0,
    "matching_method": "Reference Filter",
    "analysis_summary": "Validation skipped: Reference Missing",
    "confidence_band": "LOW"
  },
  {
    "statement": "clindamycin. 5.5-7.0. Thrombo-phlebitis. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,36",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 36..Clindamycin Injection_ Package Insert _ Prescribing Info.pdf: Thrombophlebitis has been reported after intravenous infusion. |Avoid prolonged use of indwelling intravenous catheters.",
    "validation_result": "Supported",
    "page_location": "Page 13, Local Reactions",
    "confidence_score": 0.8,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "daptomycin. 6.8. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,37,38",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 37.Daptomycin Injection_ Package Insert _ Prescribing Info.pdf: Because only limited data are available on the compatibility of daptomycin for injection with other IV substances, additives and other medications should not be added to daptomycin for injection single-dose vials or infusion bags, or infused simultaneously with daptomycin for injection through the same IV line. |If the same IV line is used for sequential infusion of different drugs, the line should be flushed with a compatible intravenous solution before and after infusion with daptomycin for injection.\n- 38.Cubicin RF (Daptomycin Injection)_ Side Effects, Uses, Dosage, Interactions, Warnings.pdf: The pH of the solution upon reconstitution is 6.8.",
    "validation_result": "Supported",
    "page_location": "Page 10-11, section 2.9 Incompatibilities | Page 4, Description for Cubicin RF",
    "confidence_score": 0.975,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "dalbavancin. Phlebitis. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,39,40",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/2 support)",
    "matched_evidence": "- 39.Dalbavancin Side Effects_ Common, Severe, Long Term.pdf: Uncommon (0.1% to 1%): Flushing, phlebitis",
    "validation_result": "Supported",
    "page_location": "Page 4, Cardiovascular section",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "delafloxacin meglumine. NR*. Phlebitis. Potential for damage from extravasation. Thrombosis of vessel. Local site pain on Infusion. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,41",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 41.Delafloxacin-Baxdela_ Package Insert _ Prescribing Information.pdf: The following selected adverse reactions were reported in BAXDELA-treated patients at a rate of less than 2% in the ABSSSI (Trials 1 and 2) and CABP (Trial 3) clinical trials:|General disorders and administration site conditions: infusion related reactions",
    "validation_result": "Supported",
    "page_location": "Page 14, Adverse Reactions Occurring in Less Than 2% of Patients Receiving BAXDELA in the ABSSSI (Trials 1 and 2) and CABP (Trial 3) Clinical Trials",
    "confidence_score": 0.8,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "doripenem. 4.5-5.5. Phlebitis. Thrombo-phlebitis. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "42,43",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 42.Doripenem_ Package Insert _ Prescribing Information.pdf: Doripenem for Injection (doripenem monohydrate) vials contain 500 mg of doripenem on an anhydrous basis, a white to slightly-yellowish off-white sterile crystalline powder. |All references to doripenem activity are expressed in terms of the active doripenem moiety. |The powder is constituted for intravenous infusion. |The pH of the infusion solution is between 4.5 and 5.5.|Most common adverse reactions (≥ 5%) are headache, nausea, diarrhea, rash and phlebitis.",
    "validation_result": "Supported",
    "page_location": "Page 13, Page 2",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "doxycycline hyclate. 1.8-3.3. Thrombo-phlebitis. Potential for damage from extravasation. Absolute vein patency needed.",
    "reference_no": "1,44",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 44.Doxycycline Injection_ Package Insert _ Prescribing Info.pdf: pH of the reconstituted solution (10 mg/mL) is between 1.8 and 3.3.|If intravenous therapy is given over prolonged periods of time, thrombophlebitis may result.",
    "validation_result": "Supported",
    "page_location": "Page 2, Page 10",
    "confidence_score": 0.85,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "eravacycline. 5.5-7.0. Phlebitis. Thrombo-phlebitis. Local site pain on Infusion. Redness at injection site. Absolute vein patency needed. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,45,46",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 45.Eravacycline Side Effects_ Common, Severe, Long Term.pdf: Common (1% to 10%): Hypotension, thrombophlebitis (includes thrombophlebitis, infusion site thrombosis), phlebitis (includes phlebitis, infusion site phlebitis, superficial phlebitis, injection site phlebitis)|Common (1% to 10%): Infusion site reactions (includes catheter/vessel puncture site pain, infusion site extravasation, infusion site hypoesthesia, infusion/injection site phlebitis, infusion site thrombosis, injection site/vessel puncture site erythema, phlebitis, superficial phlebitis, thrombophlebitis, vessel puncture site swelling, injection site pain/discomfort, injection site swelling/inflammation), infusion site phlebitis\n- 46.eravacycline - Xerava_ Package Insert _ Prescribing Information.pdf: Each 50 mg single-dose vial contains 50 mg of eravacycline (equivalent to 63.5 mg of eravacycline dihydrochloride) and the excipient, mannitol (150 mg). Sodium hydroxide and hydrochloric acid are used as needed for pH adjustment to 5.5 to 7.0.|Each 100 mg single-dose vial contains 100 mg of eravacycline (equivalent to 127 mg of eravacycline dihydrochloride) and the excipient, mannitol (150 mg). Sodium hydroxide and hydrochloric acid are used as needed for pH adjustment to 5.5 to 7.0.|Infusion site reactions include: catheter/vessel puncture site pain, infusion site extravasation, infusion site hypoaesthesia, infusion/injection site phlebitis, infusion site thrombosis, injection site/vessel puncture site erythema, phlebitis, phlebitis superficial, thrombophlebitis, and vessel puncture site swelling.|XERAVA may be administered intravenously through a dedicated line or through a Y-site. If the same intravenous line is used for sequential infusion of several drugs, the line should be flushed before and after infusion of XERAVA with 0.9% Sodium Chloride Injection, USP.",
    "validation_result": "Supported",
    "page_location": "Page 4 and 5, Cardiovascular and Local sections | Page 12, Page 8, Page 5",
    "confidence_score": 0.925,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "ertapenem. 7.5. Phlebitis. Thrombo-phlebitis. Local site pain on Infusion. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,47",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 47.Ertapenem Monograph for Professionals - Drugs.com.pdf: Gl effects (diarrhea, nausea, vomiting); local reactions (infused vein complication, phlebitis/thrombophlebitis); headache; vaginitis.",
    "validation_result": "Supported",
    "page_location": "Page 7, under Common Adverse Effects",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "erythromicin lactobionate. 6.5-7.7. Local site pain on Infusion. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,48",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 48.Erythrocin Injection_ Package Insert _ Prescribing Info.pdf: The pH of the reconstituted solution is 6.5 - 7.5.|Side effects following the use of intravenous erythromycin are rare. Occasional venous irritation has been encountered, but if the infusion is given slowly, in dilute solution, preferably by continuous intravenous infusion or intermittent infusion in no less than 20 to 60 minutes, pain and vessel trauma are minimized.|Erythrocin Lactobionate-IV (erythromycin lactobionate for injection, USP) must be administered by continuous or intermittent intravenous infusion only. Due to the irritative properties of erythromycin, IV push is an unacceptable route of administration.",
    "validation_result": "Supported",
    "page_location": "Page 2, Page 11, Page 11",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "fosfomycin. Phlebitis. Local site pain. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "49",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 49.Fosfomycin Monograph.pdf: Table 6: Adverse Drug Reactions reported by System Organ Class | System Organ Class: General disorders and administration site conditions | Frequency: Common | Adverse Drug Reactions: Injection site phlebitis | Pain, burning, redness or swelling along the vein being used for infusion of this medicine",
    "validation_result": "Supported",
    "page_location": "Page 13, Page 22",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "flucloxacillin. Phlebitis. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "50,51",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/2 support)",
    "matched_evidence": "- 51.Flucloxacillin 1.pdf: General disorders and administration site conditions: Phlebitis has followed intravenous infusion.",
    "validation_result": "Supported",
    "page_location": "Page 4, under section 4.8 Undesirable effects",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "gentamicin sulfate. 3.0-5.5. Phlebitis. Thrombo-phlebitis. Local site pain. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,52",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 52.Gentamicin Sulfate Injection Concentrate_ Package Insert _ Prescribing Info.pdf: Gentamicin Sulfate Injection, USP is administered by intravenous infusion only after dilution in a 50 or 100 mL ADD-Vantage Flexible Diluent Container of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP (See INSTRUCTIONS FOR USE).|The pH is 4.5 (3.0 to 5.5).|Other reported adverse reactions possibly related to gentamicin include: Respiratory depression, lethargy, confusion, depression, visual disturbances, decreased appetite, weight loss and hypotension and hypertension; rash, itching, urticaria, generalized burning, laryngeal edema, anaphylactoid reactions, fever, and headache; nausea, vomiting, increased salivation, and stomatitis; purpura, pseudotumor cerebri, acute organic brain syndrome, pulmonary fibrosis, alopecia, joint pain, transient hepatomegaly and splenomegaly.|Gentamicin sulfate should not be physically premixed with other drugs, but should be administered separately in accordance with the recommended route of administration and dosage schedule.",
    "validation_result": "Supported",
    "page_location": "Page 12, Page 3, Page 14, Page 12",
    "confidence_score": 0.85,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "imipenem-cilastatin. 6.5-8.5. Phlebitis. Thrombo-phlebitis. Local site pain. Redness at injection site. Rotation of peripheral infusion sites recommended. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,53",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 53.Imipenem_Cilastatin Monograph for Professionals - Drugs.com.pdf: Adults: Most common adverse effects (>0.2%) include local reactions at the IV infusion site (phlebitis, pain, erythema, vein induration), GI effects (nausea, diarrhea, vomiting), rash, pruritus, urticaria, fever, hypotension, seizures, dizziness, somnolence.",
    "validation_result": "Supported",
    "page_location": "Page 10, under Common Adverse Effects",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "meropenem and\nvaborbactam. Phlebitis. Thrombosis of vessel. Local site pain. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,54,55",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 54..Meropenem and vaborbactam Uses, Side Effects & Warnings.pdf: Common side effects of meropenem and vaborbactam may include: | • swelling or irritation where the medicine was injected.\n- 55.Meropenem and Vaborbactam (Vabomere) Full Prescribing Information. U.S. FDA.pdf: The most frequently reported adverse reactions (3% or greater) in patients receiving VABOMERE in the Phase 3 cUTI trial were headache, phlebitis/infusion site reactions, and diarrhea.|Infusion site reactions include infusion/injection site phlebitis, infusion site thrombosis, and infusion site erythema.|General disorders and administration site conditions: pain",
    "validation_result": "Supported",
    "page_location": "Page 1, under the section \"Meropenem and vaborbactam side effects\" | Page 7, Page 8, Page 9",
    "confidence_score": 0.85,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "netilmicin. 3.5-6.0. Local site pain. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "55,57",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 55.Meropenem and Vaborbactam (Vabomere) Full Prescribing Information. U.S. FDA.pdf: The most frequently reported adverse reactions (3% or greater) in patients receiving VABOMERE in the Phase 3 cUTI trial were headache, phlebitis/infusion site reactions, and diarrhea.|Infusion site reactions include infusion/injection site phlebitis, infusion site thrombosis, and infusion site erythema.|General disorders and administration site conditions: pain\n- 57.Netromax Injection (netilmicin sulfate) Package Leaflet  Information for the Patient..pdf: Netromax injections contain Netilmicin sulfate, a semi-synthetic, water-solution antibiotic of the aminoglycoside group.|Injection site or local reaction: Pain at the injection site or local reaction may occur.",
    "validation_result": "Supported",
    "page_location": "Page 1, 7, 8, 9 | Page 1, Page 5",
    "confidence_score": 0.8,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "ofloxacin. 2-9. Phlebitis. Thrombosis of vessel. Local site pain. Redness at injection site.",
    "reference_no": "58,59,60",
    "reference": "",
    "matched_paper": "Multiple PDFs (3/3 support)",
    "matched_evidence": "- 60.Qinolon (ofloxacin hydrochloride) 200 mg per 100 mL Solution for Infusion Product Information..pdf: Rare cases of phlebitis, thrombosis of vessel, local site pain, and redness at injection site have been reported with intravenous administration of ofloxacin.\n- 58.Floxin IV Side Effects_ Common, Severe, Long Term.pdf: Common (1% to 10%): Injection site reactions (including phlebitis, swelling, erythema, pain)[Ref]\n- 59.Ofloxacin (Novo-Ofloxacin) Product Monograph. Health Canada. Product Monograph..pdf: Edema, scaling and scabs at injection site (tail).",
    "validation_result": "Supported",
    "page_location": "Page 2, under ADVERSE EFFECTS | Page 10, Local, IV formulation | Page 38, Subchronic Toxicity, Rats, I.V., 4 weeks",
    "confidence_score": 0.8833333333333333,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 3 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "plazomicin. 6.5. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "61,62",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/2 support)",
    "matched_evidence": "- 62.ZEMDRI (plazomicin) Injection Full Prescribing Information. U.S. Food and Drug Administration..pdf: ZEMDRI injection 500 mg/10 mL (50 mg/mL) is supplied in single-dose, 10-mL vials fitted with flip-off seals with royal blue polypropylene buttons as a clear, colorless to yellow, sterile solution.|Each vial contains plazomicin sulfate equivalent to 500 mg plazomicin freebase at a concentration of 50 mg/mL plazomicin in Water for Injection.|Each vial contains sodium hydroxide for pH adjustment to 6.5.",
    "validation_result": "Supported",
    "page_location": "Page 21, How Supplied",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "lefamulin. 4.5-5.5. Phlebitis. Local site pain. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,63",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 63.XENLETA (lefamulin) Injection and Tablets Highlights of Prescribing Information..pdf: Table 2: Adverse Reactions Occurring in ≥2% of Patients Receiving XENLETA in Trial 1\nAdministration site reactions*\n*Administration site reactions include infusion site pain, infusion site phlebitis, and injection site reaction.",
    "validation_result": "Supported",
    "page_location": "Page 7, Table 2",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "levofloxacin. 3.8-5.8. Phlebitis. Thrombo-phlebitis. Thrombosis of vessel. Local site pain. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,64,65",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 64.Levofloxacin Monograph for Professionals - Drugs.com.pdf: Do not admix with other drugs or infuse simultaneously through same tubing with other drugs.|If same administration set is used for sequential infusion of several different drugs, flush tubing before and after administration using an IV solution compatible with levofloxacin and the other drug(s).\n- 65.Levofloxacin Side Effects_ Common, Severe, Long Term.pdf: Common (1% to 10%): Phlebitis|Common (1% to 10%): Injection site reactions (pain, reddening)|Frequency not reported: coronary thrombosis|Frequency not reported: deep thrombophlebitis|redness and swelling of the skin",
    "validation_result": "Supported",
    "page_location": "Page 8, IV Infusion section | Page 11, Cardiovascular section | Page 12, Local section | Page 11, Cardiovascular section | Page 11, Cardiovascular section | Page 4, Rare side effects",
    "confidence_score": 0.8500000000000001,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "lincomycin\nhydrochloride. 3.0-5.5. Local site pain. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,66",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 66.Lincomycin Side Effects_ Common, Severe, Long Term.pdf: IM: Pain following injection, local irritation, pain induration, sterile abscess formation|• pain, redness, or hard lumps at the injection site",
    "validation_result": "Supported",
    "page_location": "Page 4 and 6",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "linezolid. 4.8. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,67",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 67.Linezolid.pdf: Zyvox\nAntibacterial (oxazolidinone)\npH 4.8",
    "validation_result": "Supported",
    "page_location": "Page 1, top of the page",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "meropenem. 7.3-8.3. Phlebitis. Thrombo-phlebitis. Potential for damage from extravasation. Thrombosis of vessel. Local site pain. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,68",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 68.Meropenem_ Package Insert _ Prescribing Information.pdf: The pH of freshly constituted solutions is between 7.3 and 8.3.|Local adverse reactions that were reported with meropenem for injection were as follows: Inflammation at the injection site (2.4%), injection site reaction (0.9%), phlebitis/thrombophlebitis (0.8%), pain at the injection site (0.4%), and edema at the injection site (0.2%).|Compatibility of Meropenem for Injection with other drugs has not been established. Meropenem for Injection should not be mixed with or physically added to solutions containing other drugs.",
    "validation_result": "Supported",
    "page_location": "Page 13, Page 9, Page 5",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "metronidazole\nhydrochloride. 4.5-7.0. Thrombo-phlebitis. Potential for damage from extravasation. Local site pain. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,69,70",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 69.Metronidazole Injection_ Package Insert _ Prescribing Info.pdf: Metronidazole Injection, USP has an osmolarity of 310 mOsmol/L (calc) and a pH of 5.5 (4.5 to 7.0).|GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS: Injection site reaction, Malaise, Face edema, Edema peripheral, Chest pain, Chills|Caution: Metronidazole Injection is to be administered by slow intravenous drip infusion only, either as a continuous or intermittent infusion.|Additives should not be introduced into Metronidazole Injection, unless compatibility is known.|If used with a primary intravenous fluid system, the primary solution should be discontinued during metronidazole infusion.\n- 70.Metronidazole Injection_ Package Insert _ Prescribing Info.pdf: Metronidazole Injection, USP has an osmolarity of 310 mOsmol/L (calc) and a pH of 5.5 (4.5 to 7.0).|Each container contains 14 mEq of sodium.|GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS: Injection site reaction, Malaise, Face edema, Edema peripheral, Chest pain, Chills|Caution: Metronidazole Injection is to be administered by slow intravenous drip infusion only, either as a continuous or intermittent infusion.|Additives should not be introduced into Metronidazole Injection, unless compatibility is known.",
    "validation_result": "Supported",
    "page_location": "Page 2, Page 15, Page 17 | Page 2, Page 15, Page 17",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "minocycline\nhydrochloride. 4.5-5.0. Thrombo-phlebitis. Potential for damage from extravasation. Absolute vein patency needed. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,71",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 71.Minocin Injection_ Package Insert _ Prescribing Information.pdf: When diluted in compatible solutions, the pH usually ranges from 4.5 to 6.0.|If intravenous therapy is given over prolonged periods of time, thrombophlebitis may result.|Additives or other medications should not be added to MINOCIN single-dose vials or infused simultaneously through the same intravenous line including Y-connectors.",
    "validation_result": "Supported",
    "page_location": "Page 12, Page 12, Page 13",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "moxifloxacin hydrochloride. 4.1-4.6. Phlebitis. Thrombo-phlebitis. Potential for damage from extravasation. Local site pain. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,72",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 72.Avelox I.V. Side Effects_ Common, Severe, Long Term.pdf: Uncommon (0.1% to 1%): Infusion site extravasation, infusion site thrombophlebitis/phlebitis|Common (1% to 10%): Injection site reactions, infusion site reactions|Uncommon (0.1% to 1%): Rash, pruritus, hyperhidrosis, erythema, allergic dermatitis, night sweats, urticaria, dry skin",
    "validation_result": "Supported",
    "page_location": "Page 12, Local side effects | Page 13, Dermatologic side effects",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "nafcillin sodium. 6-8.5. Thrombo-phlebitis. Potential for damage from extravasation. Thrombosis of vessel. Local site pain. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,73",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 73.Nafcillin Injection (Nafcillin Sodium) RX.pdf: Nafcillin Injection, USP supplied as a premixed frozen solution is to be administered as an intravenous infusion.|Administer slowly over at least 30 to 60 minutes to minimize the risk of vein irritation and extravasation.|With intravenous administration, particularly in elderly patients, care should be taken because of the possibility of thrombophlebitis.|Pain, swelling, inflammation, phlebitis, thrombophlebitis, and occasional skin sloughing at the injection site have occurred with intravenous administration of nafcillin (see DOSAGE AND ADMINISTRATION).|Severe tissue necrosis with sloughing secondary to subcutaneous extravasation of nafcillin has been reported.",
    "validation_result": "Supported",
    "page_location": "Page 3, Page 5",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "fosfomycin 49. Additional Consideration. IVOZFO™ (fosfomycin for injection) must be reconstituted and diluted prior to administration. Use Dextrose 5% in Water (D5W) for reconstitution of the powder. It is not\nrecommended to use Sodium Chloride containing solutions for reconstitution of IVOZFO™ due to their additional sodium load (See WARNINGS AND PRECAUTIONS). IVOZFO™™™\n(fosfomycin for injection) is intended for intravenous administration. The duration of infusion should be at least 15 minutes for a 2 gram dose, 30 minutes for a 4 gram dose and 60\nminutes for an 8 gram dose. Isolated reports from the literature indicate that extending the infusion time to up to 4 hours might reduce the risk of hypokalemia. In patients with\nhigh risk of hypokalemia, an extended infusion time (up to 4 hours for the 4g and 8g strengths) might be considered. Fosfomycin solutions should not be mixed together with other\nparenteral preparations. 49",
    "reference_no": "49",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 49.Fosfomycin Monograph.pdf: IVOZFO™™ (fosfomycin for injection) must be reconstituted and diluted prior to administration. Use Dextrose 5% in Water (D5W) for reconstitution of the powder. It is not recommended to use Sodium Chloride containing solutions for reconstitution of IVOZFO™™ due to their additional sodium load (See WARNINGS AND PRECAUTIONS).|IVOZFO™™ (fosfomycin for injection) is intended for intravenous administration. The duration of infusion should be at least 15 minutes for a 2 gram dose, 30 minutes for a 4 gram dose and 60 minutes for an 8 gram dose.|Isolated reports from the literature indicate that extending the infusion time to up to 4 hours might reduce the risk of hypokalemia. In patients with high risk of hypokalemia, an extended infusion time (up to 4 hours for the 4g and 8g strengths) might be considered.|Although no chemical/pharmaceutical incompatibilities have been found, fosfomycin solutions should not be mixed together with other parenteral preparations.",
    "validation_result": "Supported",
    "page_location": "Page 6 and 8",
    "confidence_score": 1.0,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "flucloxacillin 50,51. Additional Consideration. It is advisable not to combine flucloxacillin with other drugs in solution for parenteral administration. 50",
    "reference_no": "50,51",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 50.Flucloxacillin.pdf: It is advisable not to combine flucloxacillin with other drugs in solution for parenteral administration.\n- 51.Flucloxacillin 1.pdf: Flucloxacillin may be administered in combination with other antibiotics including ampicillin to produce a wider spectrum of antibacterial activity. | If used concurrently with an aminoglycoside the two antibiotics should not be mixed in the syringe, container or giving set as precipitation may occur. | Flucloxacillin should not be mixed with blood products or other proteinaceous fluids (e.g. protein hydrolysates) or with intravenous lipid emulsions. | The following drugs are incompatible with flucloxacillin: amiodarone, atropine sulphate, buprenorphine, calcium gluconate, chlorpromazine hydrochloride, ciprofloxacin, clarithromycin, diazepam, dobutamine, hydrochloride, erythromycin lactobionate, gentamicin sulphate, metoclopramide hydrochloride, morphine sulphate, netilmicin sulphate, ofloxacin, papaveretum, pethidine hydrochloride, prochlorperazine edisylate, promethazine hydrochloride, tobramycin and verapamil hydrochloride.",
    "validation_result": "Supported",
    "page_location": "Section 6.2 Incompatibilities, page 6 | Section 6.2 Incompatibilities, page 5",
    "confidence_score": 0.975,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "gentamicin sulfate 1,52. Additional Consideration. Do not physically premix with other drugs. Inactivated in solution with beta-lactam antibiotics and vancomycin. Appropriate spacing required because of incompatibilities.¹",
    "reference_no": "1,52",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 52.Gentamicin Sulfate Injection Concentrate_ Package Insert _ Prescribing Info.pdf: Gentamicin sulfate should not be physically premixed with other drugs, but should be administered separately in accordance with the recommended route of administration and dosage schedule.",
    "validation_result": "Supported",
    "page_location": "Page 14, under the heading \"For Intravenous Administration\"",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "imipenem-cilastatin 1,53. Additional Consideration. Do not mix with or physically add other antibiotics. May be given through y-tube or three-way stopcock of infusion set. Use small needles and large veins, and rotate infusion sites.¹",
    "reference_no": "1,53",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 53.Imipenem_Cilastatin Monograph for Professionals - Drugs.com.pdf: Do not admix with other antibacterials.",
    "validation_result": "Supported",
    "page_location": "Page 4, Reconstitution and Dilution",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "meropenem and\nvaborbactam 1,54,55. Additional Consideration. Only compatible with NS. A single dose as an infusion equally distributed over 3 hours.¹",
    "reference_no": "1,54,55",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 54..Meropenem and vaborbactam Uses, Side Effects & Warnings.pdf: Meropenem and vaborbactam is usually given every 8 to 12 hours for up to 14 days. This medicine\nmust be given slowly, and the infusion can take about 3 hours to complete.\n- 55.Meropenem and Vaborbactam (Vabomere) Full Prescribing Information. U.S. FDA.pdf: The recommended dosage of VABOMERE is 4 grams (meropenem 2 grams and vaborbactam 2 grams) administered every 8 hours by intravenous (IV) infusion over 3 hours in patients 18 years of age and older with an estimated glomerular filtration rate (eGFR) greater than or equal to 50 mL/min/1.73m².|VABOMERE solution for administration by 3-hour infusion is only compatible with 0.9% Sodium Chloride Injection, USP.",
    "validation_result": "Supported",
    "page_location": "Page 3, under the section \"Meropenem and vaborbactam Uses, Side Effects & Warnings\" | Page 2, Section 2.1 | Page 4, Section 2.4",
    "confidence_score": 0.925,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "netilmicin 55,57. Additional Consideration. Ofloxacin solution for infusion should be administered only by slow IV infusion over a period of 30-60 minutes. Fluoroquinolones, including ofloxacin, are associated with an\nincreased risk of tendinitis and tendon rupture in all ages. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in\npatients with kidney, heart or lung transplants. Fluoroquinolones, including ofloxacin, may exacerbate muscle weakness in persons with myasthenia gravis. Avoid ofloxacin in patients\nwith known history of myasthenia gravis. 60",
    "reference_no": "55,57",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/2 support)",
    "matched_evidence": "- 57.Netromax Injection (netilmicin sulfate) Package Leaflet  Information for the Patient..pdf: Netromax injections contain Netilmicin sulfate, a semi-synthetic, water-solution antibiotic of the aminoglycoside group.",
    "validation_result": "Supported",
    "page_location": "Page 1, section 1",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "ofloxacin 58,59,60. Additional Consideration. Administer ZEMDRI 15 mg/kg every 24 hours by intravenous (IV) infusion over 30 minutes to patients 18 years of age or older with creatinine clearance greater than or equal to 90\nmL/min. ZEMDRI should not be mixed with other drugs or physically added to solutions containing other drugs. Other medications should not be infused simultaneously with\nZEMDRI through the same IV line.62",
    "reference_no": "58,59,60",
    "reference": "",
    "matched_paper": "Multiple PDFs (3/3 support)",
    "matched_evidence": "- 60.Qinolon (ofloxacin hydrochloride) 200 mg per 100 mL Solution for Infusion Product Information..pdf: [No evidence text provided]\n- 58.Floxin IV Side Effects_ Common, Severe, Long Term.pdf: [No evidence text provided]\n- 59.Ofloxacin (Novo-Ofloxacin) Product Monograph. Health Canada. Product Monograph..pdf: None",
    "validation_result": "Not Found",
    "page_location": "N/A",
    "confidence_score": 0.03333333333333333,
    "matching_method": "Aggregated (Not Found)",
    "analysis_summary": "Consolidated results from 3 sources",
    "confidence_band": "LOW"
  },
  {
    "statement": "plazomicin 61,62. Additional Consideration. A single dose as an infusion equally distributed over 60 minutes. Do not exceed the recommended rate of administration; may increase the magnitude of QT prolongation. Do not\nadd other additives to the diluent bag because their compatibilities with lefamulin have not been established.¹",
    "reference_no": "61,62",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/2 support)",
    "matched_evidence": "- 61.Plazomicin Uses, Side Effects & Warnings.pdf: Plazomicin is given as an infusion into a vein, every 24 to 48 hours.",
    "validation_result": "Supported",
    "page_location": "Page 2, How is plazomicin given?",
    "confidence_score": 0.75,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "MEDIUM"
  },
  {
    "statement": "lefamulin 1,63. Additional Consideration. Temporarily discontinue other solutions infusing at the same site and flush tubing with compatible solutions before and after levofloxacin.¹",
    "reference_no": "1,63",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 63.XENLETA (lefamulin) Injection and Tablets Highlights of Prescribing Information..pdf: No relevant evidence found in the document.",
    "validation_result": "Not Found",
    "page_location": "N/A",
    "confidence_score": 0.0,
    "matching_method": "Aggregated (Not Found)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "LOW"
  },
  {
    "statement": "levofloxacin 1,64,65. Additional Consideration. Manufacturer lists as incompatible with kanamycin and novobiocin. Manufacturer lists the following compatibilities. Infuse properly diluted solution at a rate not to exceed 100\nmL/hr (1 Gm/hr).¹",
    "reference_no": "1,64,65",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/2 support)",
    "matched_evidence": "- 65.Levofloxacin Side Effects_ Common, Severe, Long Term.pdf: Applies to levofloxacin: oral solution, oral tablet.|Other dosage forms:\n• intravenous solution",
    "validation_result": "Supported",
    "page_location": "Page 1, under the title 'Levofloxacin Side Effects'",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "lincomycin\nhydrochloride 1,66. Additional Consideration. Manufacturer lists as incompatible at the Y-site with amphotericin B (conventional), ceftriaxone (Rocephin), chlorpromazine (Thorazine), diazepam (Valium), erythromycin\n(Erythrocin), pentamidine, phenytoin (Dilantin), and sulfamethoxazole/trimethoprim.¹",
    "reference_no": "1,66",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 66.Lincomycin Side Effects_ Common, Severe, Long Term.pdf: I am sorry, but I could not find any information about lincomycin hydrochloride 1,66 or its incompatibility with amphotericin B (conventional), ceftriaxone (Rocephin), chlorpromazine (Thorazine), diazepam (Valium), erythromycin (Erythrocin), pentamidine, phenytoin (Dilantin), and sulfamethoxazole/trimethoprim in the provided document.",
    "validation_result": "Not Found",
    "page_location": "Entire document",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Not Found)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "linezolid 1,67. Additional Consideration. Meropenem should not be mixed or physically added to solutions containing other drugs; compatibility not established.¹",
    "reference_no": "1,67",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 67.Linezolid.pdf: [No evidence text provided]",
    "validation_result": "Not Found",
    "page_location": "Entire document",
    "confidence_score": 0.0,
    "matching_method": "Aggregated (Not Found)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "LOW"
  },
  {
    "statement": "meropenem 1,68. Additional Consideration. Administer separately, discontinue the primary IV during administration and do not introduce additives into the solution.¹ Local reactions include thrombophlebitis after intravenous\ninfusion. This reaction can be minimized or avoided by avoiding prolonged use of indwelling intravenous catheters. 69 Administer by slow intravenous drip infusion only, either as a\ncontinuous or intermittent infusion. If used with a primary intravenous fluid system, the primary solution should be discontinued during metronidazole infusion.70",
    "reference_no": "1,68",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 68.Meropenem_ Package Insert _ Prescribing Information.pdf: Compatibility of Meropenem for Injection with other drugs has not been established. Meropenem for Injection should not be mixed with or physically added to solutions containing other drugs.|Local adverse reactions that were reported with meropenem for injection were as follows: Inflammation at the injection site (2.4%), injection site reaction (0.9%), phlebitis/thrombophlebitis (0.8%), pain at the injection site (0.4%), and edema at the injection site (0.2%).",
    "validation_result": "Supported",
    "page_location": "Page 5, Page 9",
    "confidence_score": 0.85,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "metronidazole\nhydrochloride 1,69,70. Additional Consideration. Additives or other medications should not be added to the minocycline vial or infused simultaneously through the same IV line, including Y-connectors. If the same IV line is used for\nsequential infusion of additional medications, the line should be flushed before and after infusion of minocycline with NS, dextrose, dextrose in saline solutions, or LR.¹",
    "reference_no": "1,69,70",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 69.Metronidazole Injection_ Package Insert _ Prescribing Info.pdf: Caution: Metronidazole Injection is to be administered by slow intravenous drip infusion only, either as a continuous or intermittent infusion. Additives should not be introduced into Metronidazole Injection, unless compatibility is known.\n- 70.Metronidazole Injection_ Package Insert _ Prescribing Info.pdf: Caution: Metronidazole Injection is to be administered by slow intravenous drip infusion only, either as a continuous or intermittent infusion. Additives should not be introduced into Metronidazole Injection, unless compatibility is known.",
    "validation_result": "Supported",
    "page_location": "Page 17, under Important Administration and Preparation Instructions | Page 17, under Important Administration and Preparation Instructions",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "minocycline\nhydrochloride 1,71. Additional Consideration. Manufacturer states, \"Other IV substances, additives, or other medications should not be added to moxifloxacin or infused simultaneously through the same IV line.\" Flush line with a\nsolution compatible to both drugs before and after administration of moxifloxacin and/or any other drug through the same IV line. May be administered through a Y-tube.¹",
    "reference_no": "1,71",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 71.Minocin Injection_ Package Insert _ Prescribing Information.pdf: Additives or other medications should not be added to MINOCIN single-dose vials or infused simultaneously through the same intravenous line including Y-connectors. |If the same intravenous line is used for sequential infusion of additional medications, the line should be flushed before and after infusion of MINOCIN with Sodium Chloride Injection USP, Dextrose Injection USP, Dextrose and Sodium Chloride Injection USP, or Lactated Ringer's Injection USP.",
    "validation_result": "Supported",
    "page_location": "Page 13, Incompatibilities",
    "confidence_score": 1.0,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "moxifloxacin\nhydrochloride 1,72. Additional Consideration. Inactivated in solution with aminoglycosides (e.g., amikacin, gentamicin). Do not mix in the same solution. Appropriate spacing and/or separate sites required. May be infused over\n5 to 10 minutes.¹",
    "reference_no": "1,72",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 72.Avelox I.V. Side Effects_ Common, Severe, Long Term.pdf: [No evidence text provided]",
    "validation_result": "Not Found",
    "page_location": "Entire document",
    "confidence_score": 0.1,
    "matching_method": "Aggregated (Not Found)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "LOW"
  },
  {
    "statement": "nafcillin sodium 1,73. Additional Consideration. IVOZFO™ (fosfomycin for injection) must be reconstituted and diluted prior to administration. Use Dextrose 5% in Water (D5W) for reconstitution of the powder. It is not\nrecommended to use Sodium Chloride containing solutions for reconstitution of IVOZFO™ due to their additional sodium load (See WARNINGS AND PRECAUTIONS). IVOZFO™™™\n(fosfomycin for injection) is intended for intravenous administration. The duration of infusion should be at least 15 minutes for a 2 gram dose, 30 minutes for a 4 gram dose and 60\nminutes for an 8 gram dose. Isolated reports from the literature indicate that extending the infusion time to up to 4 hours might reduce the risk of hypokalemia. In patients with\nhigh risk of hypokalemia, an extended infusion time (up to 4 hours for the 4g and 8g strengths) might be considered. Fosfomycin solutions should not be mixed together with other\nparenteral preparations. 49",
    "reference_no": "1,73",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 73.Nafcillin Injection (Nafcillin Sodium) RX.pdf: The document does not mention IVOZFO™ (fosfomycin for injection), reconstitution instructions, specific infusion times (15 minutes for 2g, 30 minutes for 4g, 60 minutes for 8g), or recommendations for extended infusion times to reduce hypokalemia risk. It also does not contain information about mixing fosfomycin solutions with other parenteral preparations.",
    "validation_result": "Not Found",
    "page_location": "Entire document",
    "confidence_score": 1.0,
    "matching_method": "Aggregated (Not Found)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "omadacycline. Phlebitis. Potential for damage from extravasation. Local site pain on Infusion. Redness at injection site.",
    "reference_no": "1,74",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 74.Nuzyra Package Insert  Prescribing Information.pdf: †Infusion site extravasation, pain, erythema, swelling, inflammation, irritation, peripheral swelling and skin induration.",
    "validation_result": "Supported",
    "page_location": "Page 11, Table 5: Adverse Reactions Occurring in ≥2% of Patients Receiving NUZYRA in Pooled Trials 2 and 3",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "oritavancin. 3.1-4.3. Phlebitis. Potential for damage from extravasation. Local site pain on Infusion. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,75",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 75.Orbactiv Package Insert Prescribing Info.pdf: The following selected adverse reactions were reported in ORBACTIV-treated patients at a rate of less than 1.5%: General disorders and administration site conditions: infusion site erythema, extravasation,",
    "validation_result": "Supported",
    "page_location": "Page 9, under the section '6. Adverse Reactions/Side Effects'",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "oxacillin. 6-8.5. Phlebitis. Thrombo-phlebitis. Local site pain on Infusion. Rotation of peripheral infusion sites recommended. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,76,77",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 76.Oxacillin  Davis's Drug Guide for Rehabilitation Professionals.pdf: Local: pain at IM site, phlebitis at IV site.",
    "validation_result": "Supported",
    "page_location": "Page 2, Adverse Reactions/Side Effects",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "penicillin g aqueous. 5.5-8. Phlebitis. Local site pain on Infusion. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,78",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 78.Oxacillin Injection Package Insert Prescribing Info.pdf: The pH is 6.5 (6.0 to 8.5).|With intravenous administration, particularly in elderly patients, care should be taken because of the possibility of thrombophlebitis.",
    "validation_result": "Supported",
    "page_location": "Page 2, Page 8",
    "confidence_score": 0.8,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "piperacillin-tazobactam. 5.5-6.8. Phlebitis. Local site pain on Infusion. Redness at injection site. Rotation of peripheral infusion sites recommended. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,79,80",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 79.Penicillin G Injection  Package Insert  Prescribing Info.pdf: Phlebitis and thrombophlebitis may occur, and pain at the injection site has been reported with intravenous administration.\n- 80.Piperacillin and Tazobactam Package Insert Prescribing Info.pdf: The following clinically significant adverse reactions are described elsewhere in the labeling: |Vascular disorders\nPhlebitis (1.3%)",
    "validation_result": "Supported",
    "page_location": "Page 11, Local Reactions | Page 14 and 15, Adverse Reactions/Side Effects, Table 6",
    "confidence_score": 0.9,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "rifampim. 7.8-8.8. Phlebitis. Potential for damage from extravasation. Local site pain on Infusion. Redness at injection site. Absolute vein patency needed. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,81",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 81.Piperacillin and tazobactam Uses, Side Effects & Warnings.pdf: None",
    "validation_result": "Not Found",
    "page_location": "",
    "confidence_score": 0.1,
    "matching_method": "Aggregated (Not Found)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "LOW"
  },
  {
    "statement": "sulfamethoxazole-trimethoprim. 9.5-10.5. Phlebitis. Thrombo-phlebitis. Potential for damage from extravasation. Local site pain on Infusion. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,82",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 82.Rifampin Injection Package Insert Prescribing Information.pdf: [No evidence text provided]",
    "validation_result": "Not Found",
    "page_location": "N/A",
    "confidence_score": 0.1,
    "matching_method": "Aggregated (Not Found)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "LOW"
  },
  {
    "statement": "tedizolid. 7.4-8.1. Phlebitis. Local site pain on Infusion. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,83",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 83.Sulfamethoxazole and TrimethoprimPackage Insert  Prescribing Info.pdf: None",
    "validation_result": "Not Found",
    "page_location": "",
    "confidence_score": 0.1,
    "matching_method": "Aggregated (Not Found)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "LOW"
  },
  {
    "statement": "teicoplanin. 7.2-7.8. Phlebitis. Local site pain on Infusion. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "84,85",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 84.SIVEXTRO (tedizolid phosphate) Highlights of Prescribing Information..pdf: The most common adverse reactions (>2%) in pediatric patients (12 years to less than 18 years of age) are phlebitis and increased hepatic transaminases. (6.1)|The most common adverse reactions (>2%) in pediatric patients (less than 12 years of age) are infusion- or injection-related adverse reactions and vomiting. (6.1)|*Includes adverse reactions in the following body system or organ classes: General disorders and administration site conditions, infections and infestations, injury, poisoning and procedural complications, and vascular disorders, including but not limited to, phlebitis, injection- or infusion-site pain, injection- or infusion-site swelling, injection-site erythema, injection-site induration, and infusion-related reaction.\n- 85.Teicoplanin  Injection Infusion or Oral Solution Package Leaflet..pdf: The final solution is isotonic with plasma and has a pH of 7.2-7.8.|problems where the injection was given - such as reddening of the skin, pain or swelling",
    "validation_result": "Supported",
    "page_location": "Page 1, Page 7 | Page 7, Page 5",
    "confidence_score": 0.925,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "televancin. 4.5-5.0. Phlebitis. Local site pain on Infusion. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,86",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 86.Teicoplanin (Targocid) Injection Summary of Product Characteristics..pdf: In addition, infusion-related events, such as erythema or flushing of the upper body, have been rarely reported in which the events occurred without a history of previous teicoplanin exposure and did not recur on reexposure when the infusion rate was slowed and/or the concentration decreased.",
    "validation_result": "Supported",
    "page_location": "Page 3, Adverse Reactions",
    "confidence_score": 0.8,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "ticarcillin & clavulanate. 5.5-7.5. Phlebitis. Thrombo-phlebitis. Local site pain on Infusion. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "87,88",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 87.Vibativ Package Insert  Prescribing Information.pdf: VIBATIV is administered intravenously. Because only limited data are available on the compatibility of VIBATIV with other IV substances, additives or other medications should not be added to VIBATIV single-dose vials or infused simultaneously through the same IV line.\n- 88.Clavulanate  Ticarcillin Side Effects Common, Severe, Long Term.pdf: Common (1% to 10%): Injection site phlebitis|Postmarketing reports: Injection site pain, injection site burning, injection site swelling, injection site induration, thrombophlebitis with IV administration",
    "validation_result": "Supported",
    "page_location": "Page 7, Section 3: Dosage Forms and Strengths | Page 3, Local section",
    "confidence_score": 0.875,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "tigecycline. 7.8. Phlebitis. Local site pain on Infusion. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,89,90",
    "reference": "",
    "matched_paper": "Multiple PDFs (1/1 support)",
    "matched_evidence": "- 90.Tigecycline Package Insert  Prescribing Information.pdf: The following adverse reactions were reported (<2%) in patients receiving tigecycline in clinical studies: Injection site inflammation, injection site pain, injection site reaction, septic shock, allergic reaction, chills, injection site edema, injection site phlebitis",
    "validation_result": "Supported",
    "page_location": "Page 14, Section 6.1 Clinical Trials Experience",
    "confidence_score": 0.95,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 1 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "tobramycin. 3.0-6.5. Phlebitis. Local site pain on Infusion. Redness at injection site. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,91,92",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 91.Tigecycline Side Effects Common, Severe, Long Term.pdf: Common (1% to 10%): Phlebitis|Frequency not reported: Injection site pain, injection site inflammation, injection site reaction, injection site phlebitis, injection site edema[Ref]|• swelling, tenderness, or pain at the injection site|• red streaks on the skin\n- 92.Tobramycin Package Insert  Prescribing Information.pdf: Other reported adverse reactions possibly related to tobramycin include anemia, granulocytopenia, and thrombocytopenia; and fever, rash, exfoliative dermatitis, itching, urticaria, nausea, vomiting, diarrhea, headache, lethargy, pain at the injection site, mental confusion, and disorientation.",
    "validation_result": "Supported",
    "page_location": "Page 5, 7, 8 | Page 10, Adverse Reactions/Side Effects",
    "confidence_score": 0.8,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "vancomycin. 2.5-5.0. Phlebitis. Thrombo-phlebitis. Thrombosis of vessel. Local site pain on Infusion. Absolute vein patency needed. Rotation of peripheral infusion sites recommended. No simultaneous infusion/ dedicated lumen.",
    "reference_no": "1,93,94,95",
    "reference": "",
    "matched_paper": "Multiple PDFs (2/2 support)",
    "matched_evidence": "- 94.Vancomycin Hydrochloride Package Insert Prescribing Info.pdf: Administer Vancomycin by a secure intravenous route of administration to reduce the risk of local irritation and phlebitis reactions [see Warnings and Precautions (5.8)].|Inflammation at the injection site has been reported. Vancomycin is irritating to tissue and must be given by a secure intravenous route of administration. Thrombophlebitis may occur, the frequency and severity of which can be minimized by slow infusion of the drug and by rotation of venous access sites.|General Disorders and Administration Site Conditions: General discomfort, drug fever, chills, phlebitis, injection site irritation, injection site pain and necrosis following intramuscular injection, chemical peritonitis following intraperitoneal administration (Vancomycin Injection is not approved for intramuscular and intraperitoneal administration)\n- 95.Drouet,2015.pdf: Peripheral intravenous therapy is frequently used in routine hospital practice and, due to various factors, its most common side effect is phlebitis.|The infusion of vancomycin is particularly associated with phlebitis despite its widespread use.|ntravenous (i.v.) therapy is one of the most common routine medical practices performed in hospitals, due to the increasing complexity of disease processes. Numerous complications, including phlebitis, thrombophlebitis, extravasations and infections are however associated with peripheral i.v. (p.i.v.) therapy.|Phlebitis is the most common side effect and may occur at rates ranging from 30 to 70% (1-4), depending on various factors.",
    "validation_result": "Supported",
    "page_location": "Page 5, 11, 12 | Page 1, Introduction | Page 1, Introduction",
    "confidence_score": 0.875,
    "matching_method": "Aggregated (Supported)",
    "analysis_summary": "Consolidated results from 2 sources",
    "confidence_band": "HIGH"
  },
  {
    "statement": "Reference.",
    "reference_no": "None",
    "reference": "No citation identified in the source text.",
    "matched_paper": "None",
    "matched_evidence": "The system could not identify a superscript or citation number for this specific statement in the PDF.",
    "validation_result": "Refuted",
    "page_location": "N/A",
    "confidence_score": 0.0,
    "matching_method": "",
    "analysis_summary": "This statement was extracted but has no linked reference number to validate against.",
    "confidence_band": "LOW"
  }
]